Drug class
Omega-3 polyunsaturated fatty-acid mixture; triglyceride-lowering lipid-modifying agent
Mechanism of action
The precise mechanism depends on the formulation. EPA and DHA can reduce hepatic triglyceride synthesis through reduced diacylglycerol acyltransferase activity, increased mitochondrial and peroxisomal beta-oxidation, decreased hepatic lipogenesis and increased plasma lipoprotein-lipase activity.
General use cases
- Omega-3 fatty-acid prescription products are used as an adjunct to diet to reduce triglycerides in adults with severe hypertriglyceridaemia when the specific EPA/DHA formulation and product label support this indication. Do not generalise prescription indications to all fish-oil or dietary-supplement products.
For general informational purposes only. Do not rely on, cross-reference, cite or use this information as evidence or support for legal, regulatory, commercial or other claims.
